137 related articles for article (PubMed ID: 26489923)
1. Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Adamovich E
Brachytherapy; 2015; 14(6):766-72. PubMed ID: 26489923
[TBL] [Abstract][Full Text] [Related]
2. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
[TBL] [Abstract][Full Text] [Related]
3. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.
Foster B; Jackson W; Foster C; Dess R; Abu-Isa E; McLaughlin PW; Merrick G; Hearn J; Spratt D; Liauw S; Hamstra D
Am J Clin Oncol; 2019 Apr; 42(4):382-390. PubMed ID: 30724780
[TBL] [Abstract][Full Text] [Related]
4. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Adamovich E
Brachytherapy; 2016; 15(1):79-84. PubMed ID: 26525214
[TBL] [Abstract][Full Text] [Related]
5. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
[TBL] [Abstract][Full Text] [Related]
6. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
[TBL] [Abstract][Full Text] [Related]
7. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
9. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief JH; Adamovich E; Wallner KE
Brachytherapy; 2013; 12(5):408-14. PubMed ID: 23395456
[TBL] [Abstract][Full Text] [Related]
12. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA.
Merrick GS; Galbreath RW; Butler WM; Fiano R; Adamovich E
J Contemp Brachytherapy; 2017 Aug; 9(4):297-303. PubMed ID: 28951747
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy.
Benzaquen D; Delouya G; Ménard C; Barkati M; Taussky D
Brachytherapy; 2017; 16(2):348-352. PubMed ID: 28143764
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.
King MT; Nguyen PL; Boldbaatar N; Tempany CM; Cormack RA; Beard CJ; Hurwitz MD; Suh WW; D'Amico AV; Orio PF
Cancer; 2018 Sep; 124(17):3528-3535. PubMed ID: 29975404
[TBL] [Abstract][Full Text] [Related]
16. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
[TBL] [Abstract][Full Text] [Related]
17. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
19. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer.
Cuaron J; Pei X; Cohen GN; Cox BW; Yamada Y; Zelefsky MJ; Kollmeier MA
Brachytherapy; 2015; 14(2):179-84. PubMed ID: 25500364
[TBL] [Abstract][Full Text] [Related]
20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]